• Wednesday, April 8, 2020 @ 12:00 am
  • Robust cash position at December 31, 2019 of CHF 31.5 million providing runway through 2021
  • Awarded Eurostars / Innosuisse grant of €4.85 million supporting mGlu7 NAM PTSD program
  • Additional funding of $1.6 million in 2019 from Indivior to support GABAB PAM addiction program
  • Dipraglurant pivotal registration study in PD-LID ready to start dosing patients subject to lifting of restrictions in US associated with the global Covid-19 crisis

Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year audited results for the year ended December 31, 2019 and provided a corporate update.

“We made significant progress in 2019 in advancing our pipeline of innovative in-house discovered allosteric modulators, including our priority dipraglurant levodopa-induced dyskinesia program, which is ready to start dosing patients in a pivotal registration clinical trial as soon as the Covid-19 crisis is over,” said Tim Dyer, CEO of Addex. “We also achieved important milestones in our GABAB PAM collaboration with Indivior and secured funding from Eurostars/Innosuisse to advance our mGlu7NAM program for PTSD as well as completing the listing of American Depositary Shares (ADSs) on the Nasdaq Stock Market.”

Read the full media release

You may also be interested in